Related Experiment Video
Updated: Feb 19, 2026

A Large Animal Model for Acute Kidney Injury by Temporary Bilateral Renal Artery Occlusion
Published on: February 2, 2021
Preventing Contrast-Induced Acute Kidney Injury in Egyptian Patients Undergoing Coronary Angiography: A Randomized
Sarah Sabry1,2, Mai K Ammar3, Mahmoud Taeima4
1The Cardiovascular Hospital, Ain Shams University, 110 Ibn Fadlan Street, Nasr City, Cairo, Egypt. ssabry@ecu.edu.eg.
Insights
High-dose atorvastatin and N-acetylcysteine (NAC) can help prevent contrast-induced acute kidney injury (CI-AKI) after coronary angiography. Statins demonstrated more significant CI-AKI reduction than NAC, supporting prophylactic strategies for high-risk patients.
Area of Science:
- Nephrology
- Cardiology
- Pharmacology
Background:
- Contrast-induced acute kidney injury (CI-AKI) is a significant complication following coronary angiography (CAG).
- Preventive strategies for CI-AKI are crucial, especially in patients undergoing elective CAG.
- Limited evidence exists on effective CI-AKI prevention methods in this patient population.
Purpose of the Study:
- To compare the efficacy of high-dose N-acetylcysteine (NAC) plus hydration versus high-dose atorvastatin (HDS) plus hydration versus hydration alone in preventing CI-AKI.
- To evaluate CI-AKI prevention strategies in patients undergoing elective coronary angiography.
- To assess the impact of NAC and HDS on CI-AKI incidence post-CAG.
Main Methods:
- A prospective, multi-armed randomized comparative study involving 120 patients undergoing elective CAG.
- Patients were assigned to three groups: control (hydration), NAC (1200 mg daily for 5 days + hydration), or HDS (80 mg atorvastatin 24h prior + hydration).
- CI-AKI was defined as a serum creatinine increase >25% or 0.5 mg/dL within 48 hours post-procedure.
Main Results:
- The incidence of CI-AKI was 32.5% in the control group, 20% in the NAC group, and 12.5% in the HDS group.
- High-dose atorvastatin significantly reduced CI-AKI incidence compared to the control group (RR = 1.658).
- No statistically significant differences in in-hospital clinical outcomes were observed among the three groups.
Conclusions:
- Both N-acetylcysteine and high-dose atorvastatin show potential in reducing CI-AKI incidence following coronary angiography.
- High-dose statins appear to be more effective than NAC in preventing CI-AKI.
- Prophylactic strategies, particularly high-dose statins, are supported for CI-AKI prevention in high-risk patients undergoing CAG.
Background And Objectives:
Contrast-induced acute kidney injury (CI-AKI) observed after coronary angiography (CAG) requires preventive strategies guided by clinical judgment. Evidence is still lacking regarding the prevention of CI-AKI in patients undergoing coronary angiography. This study aimed to compare the effect of a high dose of N-acetylcysteine (NAC) plus preprocedural hydration, a high dose of atorvastatin (HDS) plus preprocedural hydration, or preprocedural hydration alone on the prevention of CI-AKI in patients undergoing elective coronary angiography.
Methods:
A prospective multi-armed randomized comparative study was conducted on elective patients undergoing CAG. Patients were randomly assigned to either control group [n = 40], who received hydration with 0.9% saline started just before contrast media injection and continued for 12 h at a rate 1.0 mL/kg/min after angiography; NAC group [n = 40], who received oral NAC 1200 mg daily started 5 days before angiography and good hydration; or HDS group [n = 40], receiving one oral dose of atorvastatin 80 mg 24 h before angiography and good hydration. CI-AKI was defined as an increase in serum creatinine of > 25% of baseline or an absolute increase of 0.5 mg/dL above baseline after 48 h. Incidence of CI-AKI and incidence of complications were assessed for all groups.
Results:
The study included 120 patients. The incidence of CI-AKI was [32.5%] in the control group, [20%] in the NAC group, and [12.5%] in the HDS group. The incidence of CI-AKI was significantly lower in the high-dose statin group compared with the control group (risk ratio = 1.658; 95% CI 1.050-2.433). In-hospital clinical outcomes showed no statistical significance among the three groups.
Conclusions:
Both NAC and high-dose statins may reduce CI-AKI incidence in patients undergoing CAG, with statins showing more promising results. These findings support prophylactic strategies for CI-AKI prevention in high-risk patients undergoing CAG. In-hospital outcomes were comparable.
Clinical Trial Registration:
Clinical-Trials.gov (ID; NCT06139952, Date; December 2023).
More Related Videos
03:13Technical Refinement of a Bilateral Renal Ischemia-Reperfusion Mouse Model for Acute Kidney Injury Research
Published on: November 3, 2023
04:37Improved Home Blood Pressure Control by CT-guided Ozone-mediated Renal Denervation for Patients with Resistant Hypertension
Published on: June 6, 2025
Related Concept Videos
Acute Kidney Injury IV: Diagnostic Studies and Prevention
Imaging Studies VII: Vascular Imaging
Cardiac Catheterization I: Pre-Procedure Overview
Imaging Studies for Cardiovascular System V: CT
Imaging Studies III: Computed Tomography
Radiological Investigation I: X-ray and CT